AstraZeneca Agrees on Licensing Deal for Obesity Treatment
09 November 2023 - 9:16AM
Dow Jones News
By Joe Hoppe
AstraZeneca said it has entered an exclusive agreement with
Eccogene, licensing the latter's ECC5004 product for treating
conditions such as type-2 diabetes and obesity.
The Anglo-Swedish pharmaceutical giant said Thursday that it
will make an upfront payment of $185 million to Eccogene for
ECC5004, and up to an additional $1.825 billion in future clinical,
regulatory, and commercial milestones and tiered royalties on
product net sales.
In return, AstraZeneca is granted exclusive global rights for
the development and commercialization of Eccogene's ECC5004 small
molecule GLP-1RA, except China, where Eccogene has the right to
co-develop and co-commercialize the drug.
The product is an oral, once-daily glucagon-like peptide 1
receptor agonist, or GLP-1RA, for the treatment of obesity, type-2
diabetes and other cardiometabolic conditions.
Preliminary results from a Phase 1 clinical trial showed a
strong efficacy and safety profile, with ECC5004 showing good
tolerability, and encouraging glucose and body weight reduction
across dose levels when compared to a placebo, AstraZeneca
said.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
November 09, 2023 03:01 ET (08:01 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
